<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807091</url>
  </required_header>
  <id_info>
    <org_study_id>7910</org_study_id>
    <secondary_id>NCI-2013-00483</secondary_id>
    <secondary_id>7910</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01807091</nct_id>
  </id_info>
  <brief_title>Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome</brief_title>
  <official_title>Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies the feasibility of having induction chemotherapy in an
      outpatient setting. Patients with acute leukemia (AML) or advanced myelodysplastic syndrome
      (MDS), at least 18 years of age will be examined. Treating eligible patients with induction
      chemotherapy in an outpatient setting may save in healthcare cost and improve a patients'
      quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess the feasibility of outpatient induction therapy for acute myeloid leukemia (AML) or
      advanced myelodysplastic syndrome (MDS) by examining whether &gt; 50% of patients treated as
      outpatients can complete chemotherapy without being admitted to hospital or &lt; 5% of patients
      die within 14 days of beginning outpatient chemotherapy.

      OUTLINE:

      Patients receive outpatient induction chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2013</start_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of hospital admission</measure>
    <time_frame>During the 4-7 days of outpatient chemotherapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TRM rate</measure>
    <time_frame>During the 14 days after beginning outpatient treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Adult Acute Myeloid Leukemia</condition>
  <condition>Adult Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive outpatient induction chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Receive outpatient induction chemotherapy</description>
    <arm_group_label>Treatment (chemotherapy)</arm_group_label>
    <other_name>Chemo</other_name>
    <other_name>Chemotherapy (NOS)</other_name>
    <other_name>Chemotherapy, Cancer, General</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

               -  The signed informed consent

               -  The benefits/risks of the induction chemotherapy regimen will be reviewed, and a
                  second consent may be necessary if the regimen will be administered according to
                  a separate protocol

          -  AML (acute promyelocytic leukemia [APL] excepted) or high-risk MDS (10-19% blasts in
             marrow by morphology or flow cytometry or blood)

          -  Treatment-related mortality (TRM) score &lt; 9.21 corresponding to a TRM rate of 3% when
             chemotherapy of similar intensity as proposed here is administered to inpatients

          -  Blast count =&lt; 10,000

          -  Fibrinogen &gt; 200

          -  Afebrile with clear chest imaging and no signs of active viral, bacterial, fungal
             infection unless determined to be, at the discretion of the investigator, not
             clinically significant in the context of this study

          -  Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF)
             of 45% or greater, by multiple gated acquisition (MUGA) or echocardiogram; no ongoing
             cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart
             failure

          -  Patient must have an outpatient caregiver available

          -  Patient must live within 30 minutes of the treating physician's office during
             outpatient treatment

          -  Patient must be willing to return to the treating physician's office for outpatient
             follow-up once outpatient treatment is completed

          -  Logistical requirements:

               -  Space available in infusion room

               -  Outpatient infusion pump available if continuous infusion required

               -  Case discussed with infusion room nursing staff
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Becker</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bozeman Deaconess Hospital</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack O. Hensold</last_name>
      <phone>406-585-5070</phone>
      <email>jhensold@bdh-boz.com</email>
    </contact>
    <investigator>
      <last_name>Jack O. Hensold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas A. Rado</last_name>
      <phone>509-783-0144</phone>
      <email>research@cbho.org</email>
    </contact>
    <investigator>
      <last_name>Thomas A. Rado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EvergreenHealth Medical Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee D. Kohn</last_name>
      <phone>425-899-3953</phone>
      <email>adkohn@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Aimee D. Kohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skagit Valley Hospital</name>
      <address>
        <city>Mount Vernon</city>
        <state>Washington</state>
        <zip>98274</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiarash Kojouri</last_name>
      <phone>360-428-2146</phone>
      <email>kkojouri@skagitvalleyhospital.org</email>
    </contact>
    <investigator>
      <last_name>Kiarash Kojouri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olympic Medical Center</name>
      <address>
        <city>Port Angeles</city>
        <state>Washington</state>
        <zip>98362</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas D. Kummet</last_name>
      <phone>360-683-9895</phone>
      <email>tkummet@olympicmedical.org</email>
    </contact>
    <investigator>
      <last_name>Thomas D. Kummet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Group Health Cooperative</name>
      <address>
        <city>Redmond</city>
        <state>Washington</state>
        <zip>98052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Y. Chen</last_name>
      <phone>425-502-3690</phone>
      <email>chen.e@ghc.org</email>
    </contact>
    <investigator>
      <last_name>Eric Y. Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela S. Becker</last_name>
      <phone>206-616-1589</phone>
      <email>pbecker@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela S. Becker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multicare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Keech</last_name>
      <phone>253-403-1677</phone>
      <email>john.keech@multicare.org</email>
    </contact>
    <investigator>
      <last_name>John A. Keech</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital and Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell A. Garrison</last_name>
      <phone>509-663-8711</phone>
      <email>mgarrison@wvmedical.com</email>
    </contact>
    <investigator>
      <last_name>Mitchell A. Garrison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

